CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 425 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,456,640 | +19.0% | 64,000 | +50.2% | 0.04% | +50.0% |
| Q1 2024 | $2,903,616 | -47.7% | 42,600 | -52.0% | 0.03% | -47.2% |
| Q4 2023 | $5,552,620 | +251.5% | 88,700 | +154.9% | 0.05% | +211.8% |
| Q3 2023 | $1,579,572 | -17.4% | 34,800 | +2.2% | 0.02% | -41.4% |
| Q2 2023 | $1,912,353 | +1.4% | 34,064 | -26.6% | 0.03% | -49.1% |
| Q4 2022 | $1,886,201 | -57.0% | 46,401 | -30.9% | 0.06% | -57.1% |
| Q3 2022 | $4,386,000 | +230.0% | 67,120 | +207.1% | 0.13% | +183.0% |
| Q2 2022 | $1,329,000 | +4.8% | 21,854 | +8.2% | 0.05% | +6.8% |
| Q1 2022 | $1,268,000 | +203.3% | 20,200 | +266.1% | 0.04% | +144.4% |
| Q4 2021 | $418,000 | -46.6% | 5,518 | +14.1% | 0.02% | -21.7% |
| Q2 2021 | $783,000 | – | 4,837 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |